Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910099 | 0.88 | RAB9A (0.48) | GRM5 | |
| SCHEMBL7910093 | 0.87 | TMPRSS4 (0.49) | GRM5 | |
| SCHEMBL7910092 | 0.86 | RAB9A (0.50) | GRM5CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL7900421 | 0.82 | GRM5 (0.48) | GRM5 | |
| SCHEMBL13148101 | 0.79 | GRM5 (0.53) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 | |
| SCHEMBL7903362 | 0.78 | GRM5 (0.66) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 | |
| SCHEMBL3793552 | 0.75 | GRM5 (0.58) | GRM5KCNH2 | |
| SCHEMBL13148116 | 0.72 | TMPRSS4 (0.46) | GRM5 | |
| SCHEMBL7904776 | 0.72 | GRM5 (0.72) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 | |
| SCHEMBL7897358 | 0.71 | GRM5 (0.70) | GRM5CYP1A2CYP2C9KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | GRM5 6/4885CYP1A2 1276/4885CYP2C9 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.